Melanoma vaccine - Chiron/Duke University
Latest Information Update: 15 Aug 2007
At a glance
- Originator Chiron Technologies
- Developer Chiron Technologies; Nonindustrial source
- Class Cancer vaccines
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Malignant melanoma